Top Stocks Under 10 Based on Big Data Analytics: Returns up to 241.84% in 1 Year
Recommended Positions: Long
Forecast Length: 1 Year (04/28/2017 - 04/28/2018)
I Know First Average: 40.91%
” This year we continue the important work of laying the foundation for Sangamo as a sustainable, fully integrated company that develops, manufacturers and commercializes novel genomic therapies on our own and, where appropriate, in collaboration with industry partners. “
-Sandy Macrae, CEO of Sangamo.
[Image source: Businesswire.com]Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a clinical stage biopharmaceutical company that focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.